View Financial HealthFluroTech 配当と自社株買い配当金 基準チェック /06FluroTech配当金を支払った記録がありません。主要情報n/a配当利回り0%バイバック利回り総株主利回り0%将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesNew Risk • May 06New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$133k This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$133k free cash flow). Negative equity (-CA$302k). Revenue is less than US$1m. Market cap is less than US$10m (CA$348.1k market cap, or US$255.5k).Board Change • Jan 19No independent directorsThere are 3 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 new directors. 5 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Member of Advisory Board Elmar Prenner is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.お知らせ • Jan 12FluroTech Ltd. Announces Chief Financial Officer ChangesFluroTech Ltd. announced that effective October 6, 2025, Reem Chalhoub has been appointed as the new Chief Financial Officer. Reem Chalhoub succeeds Curtis Smith, who has departed the Company. Reem Chalhoub is a seasoned accountant with over 10 years of executive financial leadership. As a strategic financial leader, she has successfully secured more than $50 million in financing and led private equity business buyouts, bringing deep expertise in M&A transactions, investor relations, and corporate restructuring. Reem launched her career at PwC, where she worked with multinational corporations such as Bayer and Ford, contributing to large-scale audits and complex public financial reporting. She later served as the Head of Corporate Finance at Ecolab Canada, driving strategic financial initiatives at a national level. Reem offers CFO services, partnering with CEOs and investors to craft and execute high-impact financial strategies. Her ability to scale businesses and optimize financial performance makes her a trusted advisor to growth-focused companies.お知らせ • Jun 14Flurotech Ltd. Appoints Eric Corbett to Board of Directors, Effective June 12, 2025FluroTech Ltd. announce that effective June 12, 2025, Eric Corbett has been appointed to the board of directors. Mr. Corbett is the Managing Director of Oakridge Securities Inc. which operates as a capital markets and corporate finance advisory business, where he has been employed since December 2024. From August 2017 to September 2024, Mr. Corbett was part of the corporate client group at Canadian Imperial Bank of Commerce, one of Canada's largest financial institutions, where he oversaw the execution of high-profile transactions, including providing debt capital to private and public businesses to support M&A transactions, shareholder buyouts, working capital support and sponsor backed equity investments. Mr. Corbett has served as a board member of Entero Therapeutics Inc. since February 2025 and Mixed Martial Arts Group Limited (NYSE: MMA) since April 2025. Mr. Corbett holds a Bachelor of Commerce degree from McMaster University and is also a CFA charterholder. Mr. Corbett has successfully completed the FINRA Securities Industry Essentials Exam, the CSI Canadian Securities Course and the CSI Conduct & Practices Handbook. Mr. Corbett is well qualified to serve on the board due to his specialization in capital allocation and corporate finance.お知らせ • May 03FluroTech Ltd. announced that it expects to receive CAD 22 million in fundingFluroTech Ltd. announced a best effort basis private placement of 5,500,000 subscription receipts at a price of CAD 4 per share for the gross proceeds of CAD 22,000,000 on May 1, 2024. The transaction is expected to be completed in Q2 2024.お知らせ • Mar 22FluroTech Ltd., Annual General Meeting, May 17, 2024FluroTech Ltd., Annual General Meeting, May 17, 2024.お知らせ • Mar 12FluroTech Ltd. announced that it expects to receive CAD 1 million in fundingFluroTech Ltd. announced a private placement of minimum of 6,666,667 common shares at an issue price of CAD 0.075 per share for minimum gross proceeds of CAD 500,000.025 and maximum of 13,333,333 common shares at an issue price of CAD 0.075 per share for maximum gross proceeds of CAD 999,999.975 on March 11, 2024. The financing remains subject to TSXV approval.お知らせ • Dec 22+ 1 more updateFluroTech Ltd. announced that it expects to receive CAD 1 million in fundingFluroTech Ltd. announces private placement of 5,000,000 shares at an issue price of CAD 0.10 per share for minimum gross proceeds of CAD 500,000 to 10,000,000 common shares at an issue price of CAD 0.10 per share for maximum gross proceeds of CAD 1,000,000 on December 21, 2023. The financing is subject to the approval of the TSXV stock exchange.お知らせ • Jan 14FluroTech Ltd., Annual General Meeting, Mar 20, 2023FluroTech Ltd., Annual General Meeting, Mar 20, 2023.お知らせ • Jan 04An unknown individual buyer acquired FluroTest Systems Ltd from FluroTech Ltd. for CAD 1.An unknown individual buyer acquired FluroTest Diagnostic Systems Ltd. from FluroTech Ltd. for CAD 1 on December 31, 2022. An unknown individual buyer completed the acquisition of FluroTest Diagnostic Systems Ltd. from FluroTech Ltd. on December 31, 2022.Board Change • Apr 27High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 6 experienced directors. No highly experienced directors. Independent Director Brendan Miles is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Is New 90 Day High Low • Feb 23New 90-day high: CA$0.70The company is up 352% from its price of CA$0.15 on 24 November 2020. The Canadian market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Electronic industry, which is up 43% over the same period.Is New 90 Day High Low • Feb 04New 90-day high: CA$0.60The company is up 216% from its price of CA$0.19 on 05 November 2020. The Canadian market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Electronic industry, which is up 42% over the same period.Is New 90 Day High Low • Jan 15New 90-day high: CA$0.32The company is up 24% from its price of CA$0.26 on 16 October 2020. The Canadian market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Electronic industry, which is up 20% over the same period.決済の安定と成長配当データの取得安定した配当: TEST.Hの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: TEST.Hの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場FluroTech 配当利回り対市場TEST.H 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (TEST.H)n/a市場下位25% (CA)1.7%市場トップ25% (CA)5.4%業界平均 (Electronic)0.8%アナリスト予想 (TEST.H) (最長3年)n/a注目すべき配当: TEST.Hは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: TEST.Hは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: TEST.Hの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: TEST.Hが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YCA 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/06 07:39終値2026/05/04 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋FluroTech Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
New Risk • May 06New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$133k This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$133k free cash flow). Negative equity (-CA$302k). Revenue is less than US$1m. Market cap is less than US$10m (CA$348.1k market cap, or US$255.5k).
Board Change • Jan 19No independent directorsThere are 3 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 new directors. 5 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Member of Advisory Board Elmar Prenner is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.
お知らせ • Jan 12FluroTech Ltd. Announces Chief Financial Officer ChangesFluroTech Ltd. announced that effective October 6, 2025, Reem Chalhoub has been appointed as the new Chief Financial Officer. Reem Chalhoub succeeds Curtis Smith, who has departed the Company. Reem Chalhoub is a seasoned accountant with over 10 years of executive financial leadership. As a strategic financial leader, she has successfully secured more than $50 million in financing and led private equity business buyouts, bringing deep expertise in M&A transactions, investor relations, and corporate restructuring. Reem launched her career at PwC, where she worked with multinational corporations such as Bayer and Ford, contributing to large-scale audits and complex public financial reporting. She later served as the Head of Corporate Finance at Ecolab Canada, driving strategic financial initiatives at a national level. Reem offers CFO services, partnering with CEOs and investors to craft and execute high-impact financial strategies. Her ability to scale businesses and optimize financial performance makes her a trusted advisor to growth-focused companies.
お知らせ • Jun 14Flurotech Ltd. Appoints Eric Corbett to Board of Directors, Effective June 12, 2025FluroTech Ltd. announce that effective June 12, 2025, Eric Corbett has been appointed to the board of directors. Mr. Corbett is the Managing Director of Oakridge Securities Inc. which operates as a capital markets and corporate finance advisory business, where he has been employed since December 2024. From August 2017 to September 2024, Mr. Corbett was part of the corporate client group at Canadian Imperial Bank of Commerce, one of Canada's largest financial institutions, where he oversaw the execution of high-profile transactions, including providing debt capital to private and public businesses to support M&A transactions, shareholder buyouts, working capital support and sponsor backed equity investments. Mr. Corbett has served as a board member of Entero Therapeutics Inc. since February 2025 and Mixed Martial Arts Group Limited (NYSE: MMA) since April 2025. Mr. Corbett holds a Bachelor of Commerce degree from McMaster University and is also a CFA charterholder. Mr. Corbett has successfully completed the FINRA Securities Industry Essentials Exam, the CSI Canadian Securities Course and the CSI Conduct & Practices Handbook. Mr. Corbett is well qualified to serve on the board due to his specialization in capital allocation and corporate finance.
お知らせ • May 03FluroTech Ltd. announced that it expects to receive CAD 22 million in fundingFluroTech Ltd. announced a best effort basis private placement of 5,500,000 subscription receipts at a price of CAD 4 per share for the gross proceeds of CAD 22,000,000 on May 1, 2024. The transaction is expected to be completed in Q2 2024.
お知らせ • Mar 22FluroTech Ltd., Annual General Meeting, May 17, 2024FluroTech Ltd., Annual General Meeting, May 17, 2024.
お知らせ • Mar 12FluroTech Ltd. announced that it expects to receive CAD 1 million in fundingFluroTech Ltd. announced a private placement of minimum of 6,666,667 common shares at an issue price of CAD 0.075 per share for minimum gross proceeds of CAD 500,000.025 and maximum of 13,333,333 common shares at an issue price of CAD 0.075 per share for maximum gross proceeds of CAD 999,999.975 on March 11, 2024. The financing remains subject to TSXV approval.
お知らせ • Dec 22+ 1 more updateFluroTech Ltd. announced that it expects to receive CAD 1 million in fundingFluroTech Ltd. announces private placement of 5,000,000 shares at an issue price of CAD 0.10 per share for minimum gross proceeds of CAD 500,000 to 10,000,000 common shares at an issue price of CAD 0.10 per share for maximum gross proceeds of CAD 1,000,000 on December 21, 2023. The financing is subject to the approval of the TSXV stock exchange.
お知らせ • Jan 14FluroTech Ltd., Annual General Meeting, Mar 20, 2023FluroTech Ltd., Annual General Meeting, Mar 20, 2023.
お知らせ • Jan 04An unknown individual buyer acquired FluroTest Systems Ltd from FluroTech Ltd. for CAD 1.An unknown individual buyer acquired FluroTest Diagnostic Systems Ltd. from FluroTech Ltd. for CAD 1 on December 31, 2022. An unknown individual buyer completed the acquisition of FluroTest Diagnostic Systems Ltd. from FluroTech Ltd. on December 31, 2022.
Board Change • Apr 27High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 6 experienced directors. No highly experienced directors. Independent Director Brendan Miles is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Is New 90 Day High Low • Feb 23New 90-day high: CA$0.70The company is up 352% from its price of CA$0.15 on 24 November 2020. The Canadian market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Electronic industry, which is up 43% over the same period.
Is New 90 Day High Low • Feb 04New 90-day high: CA$0.60The company is up 216% from its price of CA$0.19 on 05 November 2020. The Canadian market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Electronic industry, which is up 42% over the same period.
Is New 90 Day High Low • Jan 15New 90-day high: CA$0.32The company is up 24% from its price of CA$0.26 on 16 October 2020. The Canadian market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Electronic industry, which is up 20% over the same period.